CDFA

Anaheim, United States
Anaheim, United States
SEARCH FILTERS
Time filter
Source Type

Together with a growing economy and an aging population, heart diseases such as aortic stenosis are becoming more prevalent amongst the elderly population. Over the past decades, surgical aortic valve replacement (SAVR) procedures have been used to treat such diseases. However, the effectiveness of SAVR operations is limited due to complications and significant mortality risks, especially for older and higher risk patients. Venus Medtech's transcatheter aortic valve system, Venus A-valve, offers a less invasive treatment solution for inoperable and high-risk patients, who now can be treated through a minimally invasive procedure as opposed to the traditional open-heart surgery while on cardiopulmonary bypass. Given TAVR's minimally invasive nature, patients also make faster progress in post-operation recovery. The population over 75 years old in China is approximately 44 million, of which approximately 1.5 million suffer from severe aortic stenosis, and have not had effective treatment. The launch of the Venus A-valve brings about much improved prospects for these patients. China's first home-made TAVR valve Venus A-valve was successfully implanted in Fuwai Hospital on Sept. 10th, 2012. Professor Gao Ruilin spearheaded the clinical research efforts. As part of the 12th National Five-Year Plan for technological growth, the Venus A-valve registered study included 101 operative cases across leading institutions in China, including Fuwai Hospital, West China Hospital, The Second Affiliated Hospital Zhejiang University School of Medicine, Jiangsu Province Hospital and Rui Jin Hospital. In the study, implantation success rate was 95% and 30-day all-cause mortality was 5%. In the full analysis set, the incidence of composite events (all-cause mortality or severe stroke) at 12 months was 7.1%, on par with international trial results. Professor Gao Ruilin commented: "The Venus A-valve is better suited for the Chinese population and physiological characteristics, with a higher implant success rate, similar complication rates and lower 2-year mortality rate compared to earlier generation TAVR products. The approval of the Venus A-valve by the CDFA is a true blessing for Chinese patients, and a breakthrough in the cardiovascular medical device sector given this product has been approved in China earlier than any comparable imported devices. This makes history." When asked about the clinical performance of the Venus A-valve, Dr. Horst Sievert, Director of Frankfurt Cardiovascular Center, commented: "the product design is highly focused on precision, and the results are satisfactory. Overall, based on available data, the Venus A-valve is superior to global competing products, when applied on Chinese patients." Professor Xingdong Zhang, Scientist of biomaterials at National engineering Research Center for Biomaterials, gave praise to the tissue treatment technology of the Venus A-valve: "Venus-A valve's anti-calcification technology represents a significant development in the application of biological materials in the cardiovascular space, it greatly enhances the valve's durability, prolongs the valve's working life, and significantly improves the patient's experience." Ms. Nisa Leung, Managing Partner of Qiming Venture Partners, commented on Venus Medtech's recent achievements: "We really value the experience and professionalism of the team under the leadership of Mr. Eric Zi. With the launch of Venus A, we believe Venus Medtech will become a leading cardiovascular company in China, and will also open the door to compete in international markets!" Mrs. Stephanie Hui, Managing Director of Goldman Sachs (Asia) L.L.C., commented: "Being a first-to-market and innovative cardiovascular device, approved under CFDA's fast-track system, Venus A-valve is a pioneer in the space of interventional cardiology, and has set a good example for future innovation in treating cardiovascular diseases." When asked about his future strategy, Mr. Eric Zi, CEO of Venus Medtech said, "We have worked hard to get here, and at Venus Medtech, we believe in innovation through solid science. We will continue to help save lives and treat critical cardiovascular diseases at home and abroad. My vision for Venus Medtech goes beyond TAVR, as we aim to become a leader in the structured heart space. Our CE mark study for the Venus Pulmonary valve has already started as of September 2016. Our global trial for the third generation TAVR device, which embodies pre-packaged, retrievable and embolic protection features, will begin around the end of 2017. Its success should help Venus Medtech further strengthen our position in the market, and gain traction on a more global scale." To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/venus-medtechs-tavr-device-is-approved-by-cfda-creating-a-new-era-of-interventional-cardiology-in-china-300447984.html


News Article | April 17, 2017
Site: www.prweb.com

North American Professional liability Insurance Agency, LLC (NAPLIA) is pleased to announce that Hanover Insurance will be replacing Rockhill and Plaza Insurance as the underwriter of NAPLIA’s nationwide accountant’s error and omission program. The accountant’s program, now called the CPAOnePro (SM), will maintain all of the great benefits that have been a hallmark of our program since October of 2014. John Raspante, CPA, MST, CDFA heads up NAPLIA's Risk Management team. Attorney Ralph Picardi will continue to manage the Hotline and claims triage for the Accountant’s program. Both John and Ralph regularly assist clients in best practices, claims mitigation and engagement letters as well as website reviews. NAPLIA offers NASBA approved online risk management webinars which provide premium credits and CPE for qualified firms. Hanover Insurance Company, founded in 1852 and listed on the New York Stock Exchange as “THG”, is a Top 25 Property and Casualty insurance company with 42 offices in the United States and over $5 Billion in written premium. Hanover has an AM Best rating of “A” Excellent and is one of only a handful of insurance companies to be rated with AM Best since 1907. Additionally, Hanover maintains “A” ratings with both Standard and Poors and Moodys, and is a Forbes 2016 best mid-size company. North American Professional Liability Insurance Agency, LLC (NAPLIA) created an Errors and Omissions insurance program designed specifically for accounting and consulting firms called CPAOnePro. Working with CPAOnePro you can expect more than just a policy. We are dedicated to providing clients with continuous risk management and practical learning opportunities to keep firms protected, the highest quality customer service so partners can feel comfortable calling us with any issue, and a team of risk and legal experts who are ready and able to work to solve or mitigate any problem that arises. “Hanover’s vision of managing a successful Accountants Insurance Program through quality risk management aligns with NAPLIA’s experience and resources. We we are delighted to call them partners" said CFO/Partner Stephen Vono.


News Article | May 2, 2017
Site: www.prweb.com

420 College, the Marijuana Industry’s leading educational institution will host another one of its much-anticipated seminars May 6th through May 7th in Sacramento, California. The bulk of this particular seminar will focus on unpacking the recently proposed draft regulations for the state medical cannabis cultivation and licensing program. The seminar is scheduled on the heels of the release regulations and is a tremendous opportunity for hopeful cannabis industry entrepreneurs. The release of the draft regulations officially marks the start of the 45-day period where the public is encouraged to provide feedback on the proposed regulations. The California Department of Food and Agriculture or CFDA for short, has developed these regulations to establish cannabis cultivation and a track-and-trace system which is also commonly referred to as “seed-to-sale.” The CFDA is acting in accordance with the Medical Cannabis Regulation and Safety Act along with the recently passed Adult Use of Marijuana Act. CalCannabis says they are in their final stages of developing regulations which the industry as a whole will be beholden to and are now depending on public commentary to further shape said regulations. 420 College students will hear from legal experts who will summarize and synthesize the regulations into bite-size, digestible pieces of information so that they’ll be better able to provide constructive feedback to the CDFA and help shape the regulations in their favor. CalCannabis plans to take on much more than just creating regulations and issuing cultivation licenses. In fact, CalCannabis plans to create three separate licensing authorities: The Bureau of Marijuana Control, CalCannabis Cultivation Licensing, and The Office of Manufactured Cannabis Safety. Each authority will tackle a different sector of the industry to maximize efficiency and insure quality. The Bureau of Marijuana Control will be housed within the Department of Consumer Affairs and will deal with licensing dispensaries, distributors, transporters, and testing labs. The Office of Manufactured Cannabis Safety or (OMCS) will issue licenses to the manufacturers of cannabis products. Finally, CalCannabis will be housed within the Department of Food and Agriculture and will of course deal with licensing cultivators. George Boyadjian, CEO of 420 College, says, “420 College students in attendance of this seminar will have access to industry experts who not only have extensive, intimate knowledge of the industry but also play a part in shaping the very rules the students will be beholden to once they enter the industry. This is invaluable and could be the kind of insider knowledge that makes all the difference in one’s experience in the cannabis industry.”


News Article | May 17, 2017
Site: www.prnewswire.co.uk

During this period, services will be one of the fastest growing segments of the technology market for 3D printing for healthcare. 3D printing for healthcare revenues will increase in size significantly between 2017 and 2027. This brand new in-depth report on 3D printing for healthcare describes trends in the market both quantitatively and qualitatively. In recent years, this global 3D printing for healthcare market has experienced major growth, as the importance of 3D printing for healthcare in both developed and developing nations increases significantly. The key growth driver for 3D printing for healthcare is the high incidence of diseases such as cardiovascular disorders, for which products can be made quickly and locally. In addition, highly detailed and personalized 3D printing products are becoming possible. The 3D printing for healthcare industry is responding with innovative products, making full use of technological advances in the healthcare sector. Are you capturing as large a part of this market as you should be? This report will ensure you do. In particular, the 3D printing for healthcare report concentrates on the following essential aspects of the 3D printing for healthcare industry: Identification of key industrial players in the 3D printing for healthcare market. 3D Systems Inc. Arcam AB Autodesk Inc. ExOne Company H Intressenter AB Optomec, Inc. Organovo Holdings, Inc. Ponoko Limited Stratasys Ltd Voxeljet AG 3D Printing For Healthcare Technology Forecasts 2017-2027 Hardware 3D Printing For Healthcare Forecast 2017-2027 Software 3D Printing For Healthcare Forecast 2017-2027 Services 3D Printing For Healthcare Forecast 2017-202 North America 3D Printing For Healthcare Forecast 2017-2027 US 3D Printing For Healthcare Forecast 2017-2027 Canada 3D Printing For Healthcare Forecast 2017-2027 Mexico 3D Printing For Healthcare Forecast 2017-2027 South America 3D Printing For Healthcare Forecast 2017-2027 Brazil 3D Printing For Healthcare Forecast 2017-2027 Argentina 3D Printing For Healthcare Forecast 2017-2027 Paraguay 3D Printing For Healthcare Forecast 2017-2027 Bolivia 3D Printing For Healthcare Forecast 2017-2027 Rest of South America 3D Printing For Healthcare Forecast 2017-2027 Europe 3D Printing For Healthcare Forecast 2017-2027 UK 3D Printing For Healthcare Forecast 2017-2027 Germany 3D Printing For Healthcare Forecast 2017-2027 France3D Printing For Healthcare Forecast 2017-2027 Italy 3D Printing For Healthcare Forecast 2017-2027 Spain 3D Printing For Healthcare Forecast 2017-2027 Rest of Europe 3D Printing For Healthcare Forecast 2017-2027 Asia-Pacific 3D Printing Forecast 2017-2027 Japan 3D Printing For Healthcare Forecast 2017-2027 China 3D Printing For Healthcare Forecast 2017-2027 India 3D Printing For Healthcare Forecast 2017-2027 Australia 3D Printing For Healthcare Forecast 2017-2027 Thailand 3D Printing For Healthcare Forecast 2017-2027 Rest of APAC 3D Printing For Healthcare Forecast 2017-2027 RoW 3D Printing For Healthcare Forecast 2017-2027 Middle East 3D Printing For Healthcare Forecast 2017-2027 Africa 3D Printing For Healthcare Forecast 2017-2027 Other 3D Printing For Healthcare Forecast 2017-2027 Coverage of future trends in 3D printing for healthcare, formulation and manufacturing Examination of strengths, weaknesses, opportunities and threats facing the 3D printing for healthcare industry In-depth analysis of the 3D printing for healthcare pipeline The 3D Printing For Healthcare World Market 2017-2027 examines the 3D printing for healthcare market comprehensively, using unique primary and secondary research. Exclusively, visiongain have applied their in-house analytical techniques for forecasting with analysis of drivers and restraints. Now available to you this comprehensive market-based report provides detailed market analyses, forecasts and informed opinion which will be vital to your company's development. Visiongain predicts that 3D printing for healthcare will significantly expand for healthcare, contributing to rapid revenue growth during the period 2017 to 2027. Why you should buy this report: To receive a comprehensive analysis of the prospects for 3D printing for healthcare To receive forecasts of 3D printing for healthcare sales in leading country markets from 2017-2027 To determine the forces that influence the market for 3D printing for healthcare: drivers, restraints, opportunities and threats To find out where the 3D printing for healthcare market is heading - both technologically and commercially from 2017-2027 This report features news, insights, the latest developments and an in depth survey of the 3D printing for healthcare market with up-to-date analysis as well as tables, graphs and charts. This report is a vital addition to gaining an understanding of this market sector and will give your company 'the edge' on your competitors. You cannot afford to be without this latest report from visiongain. Target audience • Anyone within the healthcare sector • 3D printing hardware companies • 3D material suppliers • Medical device specialists • Pharmaceutical companies • Scientists • Medical doctors • Technologists • R&D staff • NPD specialists • Consultants • Analysts • CEO's • CIO's • COO's • Business development managers • Investors • Governments • Agencies • Industry organisations • Banks 3D Printing for Healthcare World Market 2017-2027: Forecasts by Products (Dental Products, Medical Implants, Bio-Printing, Others), by Technology (Hardware, Software, Services) & Analysis of Opportunities in Personalised Medicine, Medical Devices, Tailor Made Prosthetics, Orthopaedic Implants & Drugs To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100 D Systems Corporation 3t Rpd 4web Medical Alphaform AG Anatomics Ansys, Inc. Aortica Aprecia Pharmaceuticals Arcam AB Autodesk Inc. B3kd Bestinclass SA Bio 3D Technologies Biomet Inc. Blohm Jung Boeing Company Botobjects C&A Tool Carlyle Group Compass3D Delcam Deloitte Consulting, LLC Dentca Depuy Synthes Disanto Technology, Inc. Envisiontec Eos Exone Company Fabrx Firstsurface Ltd. Fripp Design And Research General Electric Gic Holdings Global Tct Grid Logic Incorporated H Intressenter Ab Hafner's Büro Hewlett-Packard Imaginarium Ipsen Laser Zentrum Hannover (LZH) Lockheed Martin Machin-A-Mation Corporation (MAM) Makerbot Materialise Nv Mechmotion Medical Modelling Mtu Aero Engines Multistation Mwt Northrop Grumman Objet Ltd. Optomec, Inc. Organovo Holdings, Inc Osteopore International Oxford Performance Materials (OPM) Pemex Ponoko Limited Proto Labs Protosys Technologies Qatar Rail Rainbow Biosciences Rede D'or São Luiz Regenhu Renishaw Replica 3DM Robotec Scansource, Inc. Siemens Siemens Corporation Sixense Stratasys Ltd. Stryker Techsolve Teijin Nakashima Medical The Cronin Group Tissue Regeneration Systems Toshiba Tronrud United Technologies Varinex Informatics Viwa Voxeljet AG Within Technologies Limited Wohlers Associates, Inc. Wynit Xerox Xilloc Medical Zdravprint Zimmer Biomet Organisations Mentioned Aida- Tecnocampus De Mataro America Makes Asian Manufacturing Association (AMA) Brazilian National Health System (Sus) China 3D Printing Technology Industry Alliance Chinese Food And Drug Administration (CDFA) Chinese Ministry Of Science And Technology Chinese National Engineering Research Centre Of Rapid Manufacturing Clemson University Commonwealth Scientific And Industrial Research Organisation's (CSIRO) Lab 22 Department Of Medical Services At The Ministry Of Public Health (Thailand) EU Council European Commission Food & Drug Administration (FDA) Government Workers' Social Security And Services Institute (ISSSTE) Italian Digital Biomanufacturing Network (IDBN) Kyoto University Graduate School Of Medicine Mexican Ministry Of National Defence (SEDENA) Mexican Ministry Of The Navy (SEMAR) Mexican Social Security Institute (IMSS) Massachusetts Institute Of Technology (MIT) Michigan Technological University Nanyang Technological University National Am Innovation Institute (NAMII) National Institutes Of Health (NIH) National Renewable Energy Laboratory (NREL) National Health Service (NHS) North Carolina State University Organisation For Economic Cooperation & Development (OECD) Salamanca Hospital (Spain) Salamanca University Hospital (Spain) Singapore Centre For 3D Printing (SC3DP) Singapore National Research Foundation Southampton General Hospital (UK) UCL School Of Pharmacy United Nations University Of California University Of Glasgow University Of Groningen University Of Northern Iowa University Of Sheffield Advanced Manufacturing Centre (AMRC) University Of Texas At El Paso US Army Research Laboratory Wake Forest Institute For Regenerative Medicine (WFIRM) World Bank World Health Organisation (WHO) World Intellectual Property Organisation (WIPO) To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


News Article | May 17, 2017
Site: www.prnewswire.com

During this period, services will be one of the fastest growing segments of the technology market for 3D printing for healthcare. 3D printing for healthcare revenues will increase in size significantly between 2017 and 2027. This brand new in-depth report on 3D printing for healthcare describes trends in the market both quantitatively and qualitatively. In recent years, this global 3D printing for healthcare market has experienced major growth, as the importance of 3D printing for healthcare in both developed and developing nations increases significantly. The key growth driver for 3D printing for healthcare is the high incidence of diseases such as cardiovascular disorders, for which products can be made quickly and locally. In addition, highly detailed and personalized 3D printing products are becoming possible. The 3D printing for healthcare industry is responding with innovative products, making full use of technological advances in the healthcare sector. Are you capturing as large a part of this market as you should be? This report will ensure you do. In particular, the 3D printing for healthcare report concentrates on the following essential aspects of the 3D printing for healthcare industry: Identification of key industrial players in the 3D printing for healthcare market. 3D Systems Inc. Arcam AB Autodesk Inc. ExOne Company H Intressenter AB Optomec, Inc. Organovo Holdings, Inc. Ponoko Limited Stratasys Ltd Voxeljet AG 3D Printing For Healthcare Technology Forecasts 2017-2027 Hardware 3D Printing For Healthcare Forecast 2017-2027 Software 3D Printing For Healthcare Forecast 2017-2027 Services 3D Printing For Healthcare Forecast 2017-202 North America 3D Printing For Healthcare Forecast 2017-2027 US 3D Printing For Healthcare Forecast 2017-2027 Canada 3D Printing For Healthcare Forecast 2017-2027 Mexico 3D Printing For Healthcare Forecast 2017-2027 South America 3D Printing For Healthcare Forecast 2017-2027 Brazil 3D Printing For Healthcare Forecast 2017-2027 Argentina 3D Printing For Healthcare Forecast 2017-2027 Paraguay 3D Printing For Healthcare Forecast 2017-2027 Bolivia 3D Printing For Healthcare Forecast 2017-2027 Rest of South America 3D Printing For Healthcare Forecast 2017-2027 Europe 3D Printing For Healthcare Forecast 2017-2027 UK 3D Printing For Healthcare Forecast 2017-2027 Germany 3D Printing For Healthcare Forecast 2017-2027 France3D Printing For Healthcare Forecast 2017-2027 Italy 3D Printing For Healthcare Forecast 2017-2027 Spain 3D Printing For Healthcare Forecast 2017-2027 Rest of Europe 3D Printing For Healthcare Forecast 2017-2027 Asia-Pacific 3D Printing Forecast 2017-2027 Japan 3D Printing For Healthcare Forecast 2017-2027 China 3D Printing For Healthcare Forecast 2017-2027 India 3D Printing For Healthcare Forecast 2017-2027 Australia 3D Printing For Healthcare Forecast 2017-2027 Thailand 3D Printing For Healthcare Forecast 2017-2027 Rest of APAC 3D Printing For Healthcare Forecast 2017-2027 RoW 3D Printing For Healthcare Forecast 2017-2027 Middle East 3D Printing For Healthcare Forecast 2017-2027 Africa 3D Printing For Healthcare Forecast 2017-2027 Other 3D Printing For Healthcare Forecast 2017-2027 Coverage of future trends in 3D printing for healthcare, formulation and manufacturing Examination of strengths, weaknesses, opportunities and threats facing the 3D printing for healthcare industry In-depth analysis of the 3D printing for healthcare pipeline The 3D Printing For Healthcare World Market 2017-2027 examines the 3D printing for healthcare market comprehensively, using unique primary and secondary research. Exclusively, visiongain have applied their in-house analytical techniques for forecasting with analysis of drivers and restraints. Now available to you this comprehensive market-based report provides detailed market analyses, forecasts and informed opinion which will be vital to your company's development. Visiongain predicts that 3D printing for healthcare will significantly expand for healthcare, contributing to rapid revenue growth during the period 2017 to 2027. Why you should buy this report: To receive a comprehensive analysis of the prospects for 3D printing for healthcare To receive forecasts of 3D printing for healthcare sales in leading country markets from 2017-2027 To determine the forces that influence the market for 3D printing for healthcare: drivers, restraints, opportunities and threats To find out where the 3D printing for healthcare market is heading - both technologically and commercially from 2017-2027 This report features news, insights, the latest developments and an in depth survey of the 3D printing for healthcare market with up-to-date analysis as well as tables, graphs and charts. This report is a vital addition to gaining an understanding of this market sector and will give your company 'the edge' on your competitors. You cannot afford to be without this latest report from visiongain. Target audience • Anyone within the healthcare sector • 3D printing hardware companies • 3D material suppliers • Medical device specialists • Pharmaceutical companies • Scientists • Medical doctors • Technologists • R&D staff • NPD specialists • Consultants • Analysts • CEO's • CIO's • COO's • Business development managers • Investors • Governments • Agencies • Industry organisations • Banks 3D Printing for Healthcare World Market 2017-2027: Forecasts by Products (Dental Products, Medical Implants, Bio-Printing, Others), by Technology (Hardware, Software, Services) & Analysis of Opportunities in Personalised Medicine, Medical Devices, Tailor Made Prosthetics, Orthopaedic Implants & Drugs To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100 D Systems Corporation 3t Rpd 4web Medical Alphaform AG Anatomics Ansys, Inc. Aortica Aprecia Pharmaceuticals Arcam AB Autodesk Inc. B3kd Bestinclass SA Bio 3D Technologies Biomet Inc. Blohm Jung Boeing Company Botobjects C&A Tool Carlyle Group Compass3D Delcam Deloitte Consulting, LLC Dentca Depuy Synthes Disanto Technology, Inc. Envisiontec Eos Exone Company Fabrx Firstsurface Ltd. Fripp Design And Research General Electric Gic Holdings Global Tct Grid Logic Incorporated H Intressenter Ab Hafner's Büro Hewlett-Packard Imaginarium Ipsen Laser Zentrum Hannover (LZH) Lockheed Martin Machin-A-Mation Corporation (MAM) Makerbot Materialise Nv Mechmotion Medical Modelling Mtu Aero Engines Multistation Mwt Northrop Grumman Objet Ltd. Optomec, Inc. Organovo Holdings, Inc Osteopore International Oxford Performance Materials (OPM) Pemex Ponoko Limited Proto Labs Protosys Technologies Qatar Rail Rainbow Biosciences Rede D'or São Luiz Regenhu Renishaw Replica 3DM Robotec Scansource, Inc. Siemens Siemens Corporation Sixense Stratasys Ltd. Stryker Techsolve Teijin Nakashima Medical The Cronin Group Tissue Regeneration Systems Toshiba Tronrud United Technologies Varinex Informatics Viwa Voxeljet AG Within Technologies Limited Wohlers Associates, Inc. Wynit Xerox Xilloc Medical Zdravprint Zimmer Biomet Organisations Mentioned Aida- Tecnocampus De Mataro America Makes Asian Manufacturing Association (AMA) Brazilian National Health System (Sus) China 3D Printing Technology Industry Alliance Chinese Food And Drug Administration (CDFA) Chinese Ministry Of Science And Technology Chinese National Engineering Research Centre Of Rapid Manufacturing Clemson University Commonwealth Scientific And Industrial Research Organisation's (CSIRO) Lab 22 Department Of Medical Services At The Ministry Of Public Health (Thailand) EU Council European Commission Food & Drug Administration (FDA) Government Workers' Social Security And Services Institute (ISSSTE) Italian Digital Biomanufacturing Network (IDBN) Kyoto University Graduate School Of Medicine Mexican Ministry Of National Defence (SEDENA) Mexican Ministry Of The Navy (SEMAR) Mexican Social Security Institute (IMSS) Massachusetts Institute Of Technology (MIT) Michigan Technological University Nanyang Technological University National Am Innovation Institute (NAMII) National Institutes Of Health (NIH) National Renewable Energy Laboratory (NREL) National Health Service (NHS) North Carolina State University Organisation For Economic Cooperation & Development (OECD) Salamanca Hospital (Spain) Salamanca University Hospital (Spain) Singapore Centre For 3D Printing (SC3DP) Singapore National Research Foundation Southampton General Hospital (UK) UCL School Of Pharmacy United Nations University Of California University Of Glasgow University Of Groningen University Of Northern Iowa University Of Sheffield Advanced Manufacturing Centre (AMRC) University Of Texas At El Paso US Army Research Laboratory Wake Forest Institute For Regenerative Medicine (WFIRM) World Bank World Health Organisation (WHO) World Intellectual Property Organisation (WIPO) To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

Loading CDFA collaborators
Loading CDFA collaborators